Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Computed Tomography Coronary Angiography for the Prevention of Myocardial Infarction (The SCOT-HEART 2 Trial)

Condition:   Cardiovascular Diseases
Interventions:   Diagnostic Test: Computed tomography coronary angiography;   Other: ASSIGN Score
Sponsors:   University of Edinburgh;   British Heart Foundation;   NHS Lothian
Not yet recruiting

P3AMI Antiplatelet Trial

Condition:   Heart Attack
Interventions:   Drug: Prasugrel;   Drug: Clopidogrel;   Drug: ticagrelor
Sponsor:   The Royal Wolverhampton Hospitals NHS Trust
Completed

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Condition:   Myocardial Infarction
Interventions:   Drug: Prasugrel;   Drug: Vorapaxar;   Drug: Aspirin;   Drug: Ticagrelor
Sponsors:   University of Florida;   Merck Sharp & Dohme Corp.
Active, not recruiting

The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction

Condition:   ST Elevation Myocardial Infarction
Intervention:  
Sponsor:   The Royal Wolverhampton Hospitals NHS Trust
Completed

BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Myocardial Infarction

Conditions:   Myocardial Infarction;   Myocardial Infarction, Acute;   Myocardial Infarction Old
Intervention:   Device: BioMonitor
Sponsor:   Biotronik SE & Co. KG
Recruiting

Early Alirocumab to Reduce LDL-C in Myocardial Infarction

Conditions:   Myocardial Infarction;   Dyslipidemias
Interventions:   Drug: Alirocumab;   Drug: Atorvastatin 80mg;   Drug: Ezetimibe 10mg
Sponsors:   Imperial College London;   Regeneron Pharmaceuticals;   Baim Institute for Clinical Research
Withdrawn

Patients With Acute Myocardial Infarction

Condition:   Cardiovascular Diseases
Intervention:   Other: discharge training
Sponsor:   Celal Bayar University
Completed

Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction

Conditions:   Acute Myocardial Infarction;   Acute Myocardial Ischemia;   STEMI - ST Elevation Myocardial Infarction
Interventions:   Drug: Dutogliptin Tartrate;   Drug: Filgrastim Injectable Product;   Drug: Placebos
Sponsor:   Recardio, Inc.
Enrolling by invitation

Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)

Condition:   Acute Myocardial Infarction
Interventions:   Procedure: Post Conditioning + Primary PCI;   Procedure: Standard Primary PCI
Sponsors:   Minneapolis Heart Institute Foundation;   National Heart, Lung, and Blood Institute (NHLBI)
Completed

Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI

Conditions:   ST Segment Elevation Myocardial Infarction;   Elective Percutaneous Coronary Intervention
Interventions:   Drug: Nitroprusside Sodium;   Drug: Tirofiban Hydrochloride;   Drug: Heparinized saline
Sponsors:   The First Affiliated Hospital of Zhengzhou University;   Anyang Regional Hospital;   Huaihe Hospital of Henan University;   The First Affiliated Hospital of Henan University of Science and Technology;   Yellow River Sanmenxia hospital;   The Peoples' Hospital of Jiaozuo City;   Jincheng People’s Hospital;   The second people's Hospital of Jiyuan;   Kaifeng Central Hospital;   Lushan People’s Hospital;   Nanyang Central Hospital;   The Second People's Hospital of Pingdingshan;   Shenma Medical Group General Hospital;   Puyang People's Hospital;   Puyang Oil Field General Hospital;   The First People's Hospital of Shangqiu;   Yanshi People’s Hospital;   The First People's Hospital of Xinmi;   First Affiliated Hospital of Xinjiang Medical University;   Xinyang Central Hospital;   People's Hospital of Zhengzhou University;   Zhengzhou First People’s Hospital;   Zhengzhou Cardiovascular Hospital;   Zhengzhou Central Hospital;   The 99th Central Hospital of the People's Liberation Army;   Zhoukou Central Hospital;   The First People's Hospital of Zhumadian;   Zhumadian Central Hospital
Recruiting

Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI

Condition:   ST Elevation Myocardial Infarction
Interventions:   Drug: Prasugrel;   Drug: Ticagrelor
Sponsor:   AORTICA Group
Completed

Pharmacoinvasive Strategy vs. Primary PCI in STEMI: A Prospective Registry in a Large Geographical Area

Condition:   Myocardial Infarction, Acute
Interventions:   Other: Primary percutaneous coronary intervention;   Other: Pharmacoinvasive strategy
Sponsor:   Instituto Nacional de Cardiologia Ignacio Chavez
Recruiting

A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome
Interventions:   Device: Orsiro;   Device: Xience
Sponsors:   University Hospital Inselspital, Berne;   University of Lausanne Hospitals
Active, not recruiting

Investigating the Role of Active Versus Chronic Coronary Artery Calcification on Acute Myocardial Infarct

Condition:   Chest Pain
Intervention:  
Sponsors:   National Heart Centre Singapore;   Singapore General Hospital
Active, not recruiting

Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction

Condition:   Myocardial Infarction
Interventions:   Drug: Ramipril;   Drug: Firibastat
Sponsor:   Quantum Genomics SA
Recruiting

Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI

Condition:   STEMI - ST Elevation Myocardial Infarction
Interventions:   Drug: Bivalirudin;   Drug: Enoxaparin;   Drug: Unfractionated heparin;   Drug: Bivalirudin placebo;   Drug: Enoxaparin placebo syringe;   Drug: Unfractionated heparin placebo
Sponsors:   Beijing Anzhen Hospital;   Chinese Academy of Medical Sciences, Fuwai Hospital;   ACTION Study Group (Pitié-Salpêtrière Hospital), Paris, France
Recruiting

Vest Prevention of Early Sudden Death Trial and VEST Registry

Conditions:   Myocardial Infarction;   Ventricular Dysfunction;   Sudden Death;   Ventricular Tachycardia;   Ventricular Fibrillation
Intervention:   Device: wearable defibrillator
Sponsors:   University of California, San Francisco;   Zoll Medical Corporation
Completed

A Smartphone-based Application Post-myocardial Infarction to Manage Cardiovascular Disease Risk

Condition:   Percutaneous Coronary Intervention
Intervention:   Other: Wellframe
Sponsors:   Massachusetts General Hospital;   Boston Scientific Corporation;   Wellframe, Inc
Active, not recruiting

Early Assessment of QFR in STEMI-II

Condition:   ST Segment Elevation Myocardial Infarction
Intervention:   Diagnostic Test: Computation of quantitative flow ratio
Sponsor:   RenJi Hospital
Recruiting

An Observational Study of Natural History of Cardiovascular Diseases

Conditions:   Stroke;   Heart Attack;   TIA;   Cardiovascular Diseases
Intervention:  
Sponsors:   Imperial College London;   University of Oxford;   Clinical Trial Service Unit and Epidemiological Studies Unit
Completed

The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI

Condition:   ST Elevation Myocardial Infarction
Intervention:  
Sponsor:   Dongying Zhang
Completed

ACCESS to the Cardiac Cath Lab in Patients Without STEMI Resuscitated From Out-of-hospital VT/VF Cardiac Arrest

Conditions:   Cardiac Arrest Due to Underlying Cardiac Condition;   Ventricular Fibrillation;   Cardiopulmonary Arrest With Successful Resuscitation
Interventions:   Procedure: Initial CCL admission;   Diagnostic Test: Initial ICU admission
Sponsor:   University of Minnesota - Clinical and Translational Science Institute
Recruiting

The MOCA I Study - Microvascular Obstruction With CoFI™ System Assessment

Conditions:   STEMI - ST Elevation Myocardial Infarction;   Microvascular Obstruction
Intervention:   Device: CorFlow Controlled Flow Infusion System - CoFI™
Sponsor:   CorFlow Therapeutics AG
Recruiting

Aspirin to Target Arterial Events in Chronic Kidney Disease

Conditions:   Chronic Kidney Diseases;   Cardiovascular Diseases;   Bleeding
Intervention:   Drug: Aspirin
Sponsors:   University of Southampton;   University of Nottingham;   University of Warwick;   Nottingham University Hospitals NHS Trust;   East Kent Hospitals University NHS Foundation Trust;   University of Durham;   Epsom and St Helier University Hospitals NHS Trust
Recruiting

Intraoperative Hypotension and Perioperative Myocardial Injury

Conditions:   Myocardial Infarction Postoperative;   Myocardial Injury;   Intraoperative Complications;   Intraoperative Hypotension;   Perioperative Complication
Intervention:  
Sponsor:   Karolinska Institutet
Recruiting

Genetic Variation in Platelet Aggregation

Condition:   Myocardial Infarction
Intervention:  
Sponsor:   Vanderbilt University
Completed

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

Condition:   Acute Myocardial Infarction
Interventions:   Drug: LCZ696 (sacubitril/valsartan);   Drug: Ramipril;   Drug: Placebo of LCZ696;   Drug: Placebo of ramipril;   Drug: Valsartan;   Drug: Placebo of valsartan
Sponsor:   Novartis Pharmaceuticals
Recruiting

Quantitative Flow Ratio Guided Revascularization Strategy for Patients Undergoing Primary Valve Surgery With Comorbid Coronary Artery Disease

Conditions:   Primary Valvular Heart Disease With Comorbid Coronary Artery Disease;   Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart Disease
Interventions:   Device: QFR-guided strategy;   Other: CAG-guided strategy
Sponsors:   Ruijin Hospital;   Med-X Research Institute, Shanghai Jiao Tong University
Not yet recruiting

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed

The Acute and Chronic Effects of Remote Ischemic Conditioning on Cardiovascular Function

Condition:   Acute Myocardial Infarction
Intervention:   Device: Brachial cuff, in order to achieve ischemic stimuli
Sponsor:   University of Athens
Active, not recruiting

Glutamate for Metabolic Intervention in Coronary Surgery

Conditions:   Coronary Artery Bypass;   Myocardial Ischemia;   Myocardial Infarction;   Coronary Artery Disease
Interventions:   Drug: Intravenous infusion of saline;   Other: Intravenous glutamate infusion
Sponsors:   University Hospital, Linkoeping;   Region Örebro County;   Blekingesjukhuset, Karlskrona
Completed

Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty

Condition:   Saphenous Vein Graft Atherosclerosis
Interventions:   Device: Bare Metal Stent;   Device: Drug-Eluting Stent;   Drug: Blinded clopidogrel;   Drug: Placebo;   Drug: Thienopyridine (open-label)
Sponsor:   VA Office of Research and Development
Completed

SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Metformin;   Drug: Dapagliflozin 10 MG
Sponsors:   Uppsala University;   Uppsala University Hospital;   Swedish Healthcare Regions;   Swedish National Board of Health and Welfare;   The Swedish National Diabetes Register
Recruiting

EROSION II: OCT Guided PPCI in STEMI

Condition:   STEMI - ST Elevation Myocardial Infarction
Intervention:  
Sponsors:   Harbin Medical University;   Shenzhen Salubris Pharmaceuticals Co., Ltd. (Salubris);   CCRF
Recruiting

Disrupt CAD III With the Shockwave Coronary IVL System

Conditions:   Coronary Artery Disease;   Myocardial Infarction
Intervention:   Device: Lithotripsy
Sponsor:   Shockwave Medical, Inc.
Recruiting

Technical Development of Cardiovascular Magnetic Resonance Imaging

Conditions:   Cardiomyopathy;   Congenital Heart Disease;   Cardiovascular Disease;   Cardiac Magnetic Resonance Imaging;   Acute Myocardial Infarction
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Suspended

SORT OUT X - Combo Stent Versus ORSIRO Stent

Conditions:   Coronary Heart Disease;   Angina Pectoris;   Myocardial Infarction
Interventions:   Device: COMBO;   Device: ORSIRO
Sponsors:   Aarhus University Hospital Skejby;   Biotronik SE & Co. KG;   OrbusNeich
Active, not recruiting

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Conditions:   Type 2 Diabetes Mellitus;   Chronic Kidney Diseases
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
Sponsor:   Sanofi
Recruiting

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Completed

HIP Fracture Accelerated Surgical TreaTment And Care tracK (HIP ATTACK) Trial

Condition:   Hip Fractures
Intervention:   Other: Accelerated medical clearance and surgery
Sponsors:   McMaster University;   Population Health Research Institute;   Hamilton Health Sciences Corporation
Active, not recruiting

Genetic Factors in Atherosclerosis

Condition:   Atherosclerosis
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

Condition:   Coronary Artery Disease
Interventions:   Drug: High dose potent statin;   Drug: ACE-I (lisinopril) or ARB (losartan);   Drug: Aspirin;   Behavioral: Lifestyle Counseling;   Behavioral: Quality of Life Questionnaires
Sponsors:   University of Florida;   United States Department of Defense
Recruiting

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
Sponsor:   CSL Behring
Recruiting

ROOBY Trial Follow-up Extension

Conditions:   All Cause Mortality;   MACE
Intervention:  
Sponsor:   VA Office of Research and Development
Completed

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Conditions:   Overweight;   Obesity
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Recruiting

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Not yet recruiting

The VA Diabetes Trial Follow-up Study (VADT-FS)

Conditions:   Diabetes;   Glycemic Control
Intervention:  
Sponsor:   VA Office of Research and Development
Completed

Hepatitis C Treatment and Atherosclerosis

Conditions:   Chronic Hepatitis C;   Atherosclerosis
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

Conditions:   Arterial Occlusive Diseases;   Coronary Artery Disease;   Coronary Disease;   Arteriosclerosis;   Heart Diseases;   Myocardial Ischemia;   Vascular Diseases;   Acute Coronary Syndrome
Interventions:   Drug: PZ-128;   Drug: Placebo
Sponsors:   Tufts Medical Center;   National Heart, Lung, and Blood Institute (NHLBI);   RTI International;   Inova Fairfax Hospital;   University of Massachusetts, Worcester
Suspended

Natural History of Atherosclerosis in Real-World Patients Underwent Computed Tomography Angiography

Conditions:   Coronary Atherosclerosis;   Coronary Artery Disease;   Radiocontrast-induced Thyroid Dysfunction;   Contrast-induced Nephropathy;   Cerebrovascular Disease;   Alzheimer's Disease
Interventions:   Radiation: Coronary computed tomography angiography;   Radiation: Quantitative coronary angiography
Sponsors:   Ural Medical University;   Ural Institute of Cardiology;   De Haar Research Task Force;   Transfiguration Clinic;   First Sverdlovsk Regional Clinical Hospital
Enrolling by invitation

LEADERS FREE II: BioFreedom™ Pivotal Study

Conditions:   Acute Coronary Syndrome;   High Bleeding Risk
Interventions:   Device: BioFreedom™ Drug Coated Coronary Stent System;   Drug: Dual Antiplatelet Therapy
Sponsor:   Biosensors Europe SA
Active, not recruiting

Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease

Condition:   Kawasaki Disease
Intervention:   Drug: Anakinra
Sponsors:   University of California, San Diego;   Boston Children’s Hospital;   Cedars-Sinai Medical Center
Recruiting

XIENCE 28 USA Study

Conditions:   Bleeding Disorder;   Ischemic Stroke;   Hemorrhagic Stroke;   Hematological Diseases;   Thrombocytopenia;   Coagulation Disorder;   Anemia;   Renal Insufficiency;   Coronary Artery Disease
Interventions:   Device: XIENCE;   Drug: DAPT (aspirin and/or P2Y12 receptor inhibitor)
Sponsor:   Abbott Medical Devices
Recruiting

Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities

Condition:   Kawasaki Disease
Intervention:   Drug: Atorvastatin
Sponsors:   University of California, San Diego;   Children's Hospital Colorado;   University of Colorado, Denver
Completed

Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease

Conditions:   Atrial Fibrillation;   Coronary Artery Disease;   Stable Angina;   Stable Chronic Angina
Interventions:   Drug: Edoxaban;   Drug: Single Antiplatelet Agents
Sponsors:   Gi-Byoung Nam;   CardioVascular Research Foundation, Korea
Recruiting

Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)

Condition:   Systemic Lupus Erthematosus
Interventions:   Radiation: PET/CT;   Drug: Pioglitazone;   Procedure: Vascular function studies
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting

Insulin Resistance and Atherosclerosis in Women With Lupus

Conditions:   Systemic Lupus Erythematosus;   Insulin Resistance;   Atherosclerosis
Intervention:  
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Completed

Women's Health Initiative Strong and Healthy Study

Conditions:   Myocardial Infarction;   Stroke;   Cardiovascular Mortality;   Hip Fractures;   Falls;   Mortality;   Venous Thromboembolic Event;   Peripheral Artery Disease;   Physical Function;   Coronary Revascularization;   Mobility and Independence;   Clinical (Non-hip) Fractures
Intervention:   Behavioral: Physical Activity
Sponsors:   Fred Hutchinson Cancer Research Center;   University of California, San Diego;   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting

CoreValve® System Australia/New Zealand Clinical Study

Condition:   Aortic Valve Stenosis
Intervention:   Device: Medtronic CoreValve® System
Sponsors:   Medtronic Cardiovascular;   Medtronic Australasia
Completed

Effect of Diet on Vascular Disease in Pre-Menopausal Women

Conditions:   Cardiovascular Diseases;   Vascular Disease;   Inflammation;   Insulin;   Triglycerides
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

Condition:   Peripheral Arterial Disease
Interventions:   Drug: Clopidogrel;   Drug: Acetylsalicylic acid (ASA)
Sponsor:   University of Texas Southwestern Medical Center
Active, not recruiting

The AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) The AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) Post Approval Study

Condition:   Post-Infarction Ventricular Septal Defect
Intervention:   Device: AMPLATZER™ Post-infarct Muscular VSD Occluder
Sponsor:   Abbott Medical Devices
Recruiting

Concordance Between FFR and iFR for the Assessment of Intermediate Lesions in the Left Main Coronary Artery. A Prospective Validation of a Default Value for iFR

Conditions:   Coronary Artery Disease;   Left Main Coronary Artery Stenosis;   Left Main Coronary Artery Disease;   Restenosis, Coronary
Intervention:   Other: Indication of revascularization
Sponsor:   Fundación EPIC
Recruiting

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Condition:   Anemia in Subjects With DD-CKD
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Active, not recruiting

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Conditions:   Anemia;   Dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: Darbepoetin alfa
Sponsor:   Akebia Therapeutics
Active, not recruiting

Predicting Outcomes of PAD Patients Undergoing Endovascular Intervention With CTA

Condition:   Peripheral Artery Disease
Intervention:  
Sponsor:   First Affiliated Hospital Xi'an Jiaotong University
Not yet recruiting

Hypertension Chronobiome

Condition:   Hypertension
Intervention:   Other: Ambulatory blood pressure measurements
Sponsor:   University of Pennsylvania
Recruiting

Optimal Hemostasis Duration for Percutaneous Coronary Intervention Via Snuffbox Approach

Conditions:   Bleeding;   Artery Injury
Intervention:   Procedure: Percutaneous coronary intervention via snuffbox approach
Sponsors:   Chonnam National University Hospital;   Chungbuk National University Hospital;   City Clinical Hospital No 52, Moscow, Russia;   Wakayama Medical University;   The Catholic University of Korea
Recruiting

The FAVOR III China Study

Conditions:   Coronary Artery Disease;   Myocardial Ischaemia;   Coronary Circulation;   Coronary Stenosis;   Percutaneous Coronary Intervention
Interventions:   Diagnostic Test: QFR;   Diagnostic Test: Angiography
Sponsor:   China National Center for Cardiovascular Diseases
Recruiting

Lipa Gene Mutation in PED-LIPIGEN (Pediatric FH Subjects)

Condition:   Lysosomal Acid Lipase Deficiency
Intervention:   Other: Observational study
Sponsor:   Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
Recruiting

Increasing Cardiac Rehabilitation Participation Among Medicaid Enrollees

Condition:   Coronary Artery Disease
Intervention:   Behavioral: Financial incentives
Sponsors:   University of Vermont;   National Institute of General Medical Sciences (NIGMS)
Completed

Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF)

Condition:   Idiopathic Pulmonary Fibrosis
Intervention:  
Sponsor:   Boehringer Ingelheim
Active, not recruiting

Management of Antiplatelet Regimen During Surgical Procedures

Conditions:   Cardiac Surgery;   Anti-Platelet Medication;   Bridging;   Percutaneous Coronary Intervention
Intervention:  
Sponsors:   University of Texas Southwestern Medical Center;   Chiesi USA
Recruiting

Anti-inflammatory Effects of Colchicine in PCI

Condition:   Coronary Artery Disease
Interventions:   Drug: Colchicine;   Drug: Placebo
Sponsors:   NYU Langone Health;   Takeda
Active, not recruiting

Preoperative Pulmonary Systolic Pressure and Outcome After Non-cardiac Surgery:Threshold Analysis

Condition:   Pulmonary Hypertension
Intervention:   Other: NO intervention required
Sponsor:   Peking University First Hospital
Recruiting

Skin Sympathetic Nerve Activity and Cardiac Arrhythmias

Condition:   Sympathetic Nerve Activity
Intervention:   Other: Physiologic maneuvers
Sponsors:   Cedars-Sinai Medical Center;   National Institutes of Health (NIH)
Withdrawn

Duration Threstholds of Intraoperative Hypotension

Condition:   Hypotension
Intervention:  
Sponsor:   Peking University First Hospital
Completed

Evaluating System Change to Advance Learning and Take Evidence to Scale (ESCALATES)

Condition:   Program Evaluation
Intervention:   Behavioral: ESCALATES
Sponsors:   Oregon Health and Science University;   University of Texas;   Rutgers University;   HealthPartners Institute;   University of Michigan;   Case Western Reserve University
Active, not recruiting

Thoracoabdominal Aortic and Aortic Arch Aneurysms With Fenestrated and Branched Stent Grafts

Conditions:   Thoracoabdominal Aortic Aneurysm;   Aortic Arch Aneurysm
Interventions:   Device: Thoracoabdominal Aortic Aneurysm Arm;   Device: Aortic Arch Aneurysm Arm
Sponsors:   Gustavo S. Oderich;   William Cook Australia
Recruiting

Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice

Condition:   Atrial Fibrillation
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Apixaban (Eliquis);   Drug: Warfarin
Sponsors:   Bayer;   Janssen, LP
Active, not recruiting

Effect of Efpeglenatide on Cardiovascular Outcomes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Efpeglenatide (SAR439977);   Drug: Placebo
Sponsor:   Sanofi
Active, not recruiting

A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)

Condition:   Non-valvular Atrial Fibrillation (NVAF)
Intervention:   Drug: Rivaroxaban (Xarelto,Bay 59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Not yet recruiting

Off-pump Versus On-pump Coronary Artery Bypass Grafting in Frail Patients

Conditions:   Frail Elderly;   Coronary Artery Disease
Interventions:   Procedure: Off-pump coronary-artery bypass grafting;   Procedure: On-pump coronary-artery bypass grafting
Sponsors:   University of Sao Paulo General Hospital;   Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina de São Paulo;   Instituto de Cardiologia do Distrito Federal;   Hospital Alberto Urquiza Wanderley;   Hospital das Clínicas Samuel Libânio;   Pontifícia Universidade Católica do Paraná;   Hospital Samaritano Paulista;   Beneficência Portuguesa de São Paulo;   Hospital Samaritano Campinas;   Mount Sinai Hospital, New York
Recruiting

Naloxegol US PMR CV Safety.

Condition:   Opioid Induced Constipation
Interventions:   Drug: naloxegol;   Drug: non-PAMORA
Sponsor:   AstraZeneca
Recruiting

Comparative Effectiveness of Empagliflozin in the US

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: DPP-4 inhibitor
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting

Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Aclidinium bromide;   Drug: Other COPD medication
Sponsors:   AstraZeneca;   RTI Health Solutions
Recruiting

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )

Conditions:   Hypogonadism;   Cardiovascular Diseases
Interventions:   Drug: Testosterone;   Drug: Placebo
Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
Recruiting

Outcomes After Hypotensive Neuraxial Anesthesia in Total Hip Arthroplasty

Conditions:   Total Hip Arthroplasty;   Primary Total Hip Arthroplasty;   Hypotension;   Database
Intervention:   Other: Chart Review
Sponsor:   Hospital for Special Surgery, New York
Active, not recruiting

A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

Goal-directed Fluid Therapy in Elderly Patients Undergoing Lumbar Surgery

Conditions:   Postoperative Complications;   Fluid Overload
Intervention:   Other: Applying goal-directed fluid therapy by continuous hemodynamic monitoring system (LiDCO)
Sponsor:   Peking Union Medical College Hospital
Completed

CTO Registry From Insight of IVUS in Fuwai Hospital

Conditions:   Coronary Heart Disease;   Chronic Total Occlusion of Coronary Artery;   Percutaneous Coronary Intervention;   Intravascular Ultrasound
Intervention:  
Sponsor:   China National Center for Cardiovascular Diseases
Recruiting

RESOLUTE ONYX China Single Arm Study

Conditions:   Ischemic Heart Disease;   Stenotic Coronary Lesion;   Cardiovascular Diseases;   Arteriosclerosis;   Coronary Artery Disease
Intervention:   Device: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Sponsor:   Medtronic Vascular
Active, not recruiting

RESOLUTE ONYX China RCT Study

Conditions:   Ischemic Heart Disease;   Stenotic Coronary Lesion;   Cardiovascular Diseases;   Arteriosclerosis;   Coronary Artery Disease
Interventions:   Device: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System;   Device: Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
Sponsor:   Medtronic Vascular
Active, not recruiting

A Prospective Study on the Safety and Efficacy of Apixaban for the PReventiOn of ThromboEmbolism in Adults With Congenital HearΤ Disease and Atrial ARrhythmias

Conditions:   Congenital Heart Disease;   Atrial Fibrillation;   Thromboembolism;   Anticoagulants Causing Adverse Effects in Therapeutic Use
Intervention:   Drug: Apixaban
Sponsors:   AHEPA University Hospital;   Onassis Cardiac Surgery Centre;   Attikon Hospital;   MITERA Children's Hospital
Recruiting

Czech Multicentre Research Database of Chronic Obstructive Pulmonary Disease (COPD)

Condition:   Chronic Obstructive Airway Disease
Intervention:  
Sponsor:   Zuzana Zbožínková, M.Sc.
Active, not recruiting

EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study

Condition:   Abdominal Aortic Aneurysm Without Rupture
Intervention:   Device: Nellix® System
Sponsor:   Endologix
Recruiting

Medtronic Terminate AF Study

Conditions:   Persistent Atrial Fibrillation;   Longstanding Persistent Atrial Fibrillation
Interventions:   Procedure: Surgical Ablation;   Device: Cardioblate and Cryoflex hand held devices
Sponsor:   Medtronic Cardiovascular
Recruiting

Assessment of Patients With suspeCted Coronary Artery Disease by Coronary calciUm fiRst strATegy vErsus Usual Care Approach.

Condition:   Coronary Artery Disease
Interventions:   Diagnostic Test: PET Stress Test;   Other: Non-PET Medical Management
Sponsor:   Intermountain Health Care, Inc.
Not yet recruiting

Enhancing Cardiac Rehabilitation Through Behavioral Nudges

Conditions:   Acute Myocardial Infarction;   Percutaneous Coronary Intervention;   Coronary Artery Disease;   Valvular Disease;   Chronic Stable Angina;   Chronic Stable Heart Failure
Interventions:   Other: Hospital-based CR + Movn Application;   Other: Choice of Hospital or home-based CR + Movn Application;   Other: Hospital-based CR + Movn Application + Nudge;   Other: Choice of Hospital or home-based CR + Movn Application + Nudge
Sponsor:   Denver Health and Hospital Authority
Recruiting

Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH® SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation.

Condition:   Paroxysmal Atrial Fibrillation
Intervention:   Device: THERMOCOOL SMARTTOUCH SF-5D Catheter
Sponsor:   Biosense Webster, Inc.
Completed

Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System

Conditions:   Healthy Volunteers and Subjects With Disease;   CAD
Interventions:   Device: MRI scan x 1- Healthy volunteer;   Device: MRI scan x 2- Healthy volunteer;   Device: MRI scan x 2- CAD patients;   Device: MRI scan x 2- non-CAD patients
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting

Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal

Conditions:   Acute Bleeding on Long-Term Anticoagulation Therapy;   Hemorrhage;   Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time);   Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation
Intervention:   Drug: 4-factor prothrombin complex concentrate (4FPCC)
Sponsor:   HealthPartners Institute
Completed

Characteristics of Patients With Type 2 Diabetes Mellitus (CVD-RNDR)

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Completed

Essential Hypotension and Allostasis Registry

Conditions:   Blood Pressure;   Depression;   Panic Attack;   Fibromyalgia;   POTS;   Inappropriate Sinus Tachycardia;   Coronary Heart Disease;   Acute Coronary Syndrome (ACS);   Acute Myocardial Infarction (AMI);   Cerebrovascular Disease (CVD);   Transient Ischemic Attack (TIA);   Atrial Fibrillation;   Diabetes Mellitus;   Cancer;   Systolic Heart Failure;   Diastolic Heart Failure;   Chronic Fatigue Syndrome;   Syncope;   Vasovagal Syncope
Intervention:  
Sponsor:   CES University
Recruiting

Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes

Condition:   Coronary Artery Disease
Intervention:   Diagnostic Test: CardioFlux Magnetocardiography
Sponsor:   Genetesis Inc.
Not yet recruiting

Cryoablation System FIM/CE Mark Study

Condition:   Atrial Fibrillation
Intervention:   Device: The Cryterion Cardiac Cryoablation System
Sponsors:   Boston Scientific Corporation;   Cryterion Medical, Inc.
Recruiting

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Active, not recruiting

Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists

Condition:   Pulmonary Disease, Chronic Obstructive
Intervention:  
Sponsor:   Boehringer Ingelheim
Active, not recruiting

Effect of Ambulatory BP Monitoring on the CliniCal coUrse and RenAl ouTcomE of CKD

Conditions:   Chronic Kidney Diseases;   Renal Insufficiency, Chronic;   Albuminuria;   Hypertension
Intervention:   Device: Ambulatory blood pressure monitoring (ABPM)
Sponsors:   Seoul National University Hospital;   Kangbuk Samsung Hospital;   Severance Hospital;   Eulji General Hospital
Active, not recruiting

1-month vs 12-month DAPT for ACS Patients Who Underwent PCI Stratified by IVUS: IVUS-ACS and ULTIMATE-DAPT Trials

Condition:   Coronary Artery Disease
Interventions:   Drug: AntiPlatelet therapy;   Procedure: Percutaneous coronary intervention
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Not yet recruiting

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Research & Development, LLC
Active, not recruiting

Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention

Condition:   Percutaneous Coronary Intervention
Interventions:   Drug: Fentanyl;   Drug: Ticagrelor 90Mg Tablet
Sponsor:   The Guthrie Clinic
Recruiting

Study to Develop a Prediction Model to Understand the Effect of Low-dose Aspirin on Cancer That Develops in the Colon and/or the Rectum, Diseases That Affects the Heart or Blood Vessels and Safety Outcomes in European Countries. The Study is Also Called PEACOS Model EU

Conditions:   Colorectal Cancer;   Cardiovascular Disease;   Bleeding
Intervention:   Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Sponsor:   Bayer
Active, not recruiting

Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid

Condition:   Atherosclerosis
Interventions:   Drug: Rivaroxaban (BAY59-7939, Xarelto);   Drug: Acetylsalicylic acid
Sponsors:   Bayer;   Janssen, LP
Recruiting

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Completed

MOMENTUM 3 IDE Clinical Study Protocol

Condition:   Advanced Refractory Left Ventricular Heart Failure
Interventions:   Device: HeartMate 3 LVAS;   Device: HeartMate II LVAS
Sponsors:   Abbott Medical Devices;   Thoratec Corporation
Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Active, not recruiting

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor;   Drug: Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
Sponsor:   Boehringer Ingelheim
Active, not recruiting

Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial

Condition:   Ischaemic Stroke
Interventions:   Drug: Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®);   Drug: Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)
Sponsor:   University Hospital Inselspital, Berne
Recruiting

Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)

Conditions:   Wounds and Injuries;   Acute Coagulopathy
Interventions:   Drug: Tranexamic Acid;   Drug: Placebo
Sponsors:   Monash University;   National Health and Medical Research Council, Australia;   Health Research Council, New Zealand
Recruiting

A Study of Special Use Results Surveillance of Revlimid 5mg Capsules

Conditions:   Multiple Myeloma;   Myelodysplastic Syndromes
Intervention:  
Sponsor:   Celgene
Active, not recruiting

The CONFIDENCE Registry

Conditions:   Symptomatic Degenerative Aortic Stenosis;   Severe Aortic Stenosis
Intervention:   Device: Portico™ Valve, Delivery System(s) and Loading Systems(s)
Sponsor:   Abbott Medical Devices
Recruiting

Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean

Conditions:   Obstetrical Complications;   Hemorrhage;   Labor and Delivery
Interventions:   Drug: Tranexamic Acid;   Drug: Placebo
Sponsors:   The George Washington University Biostatistics Center;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting

An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement

Condition:   Aortic Valve Stenosis
Interventions:   Drug: NOAC;   Drug: DAPT
Sponsors:   Duk-Woo Park, MD;   CardioVascular Research Foundation, Korea;   Daiichi Sankyo Korea Co., Ltd.
Recruiting

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin;   Drug: Antiplatelet drugs
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting

SPYRAL HTN-ON MED Study

Conditions:   Hypertension;   Vascular Diseases;   Cardiovascular Diseases
Interventions:   Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
Sponsor:   Medtronic Vascular
Recruiting

SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study

Conditions:   Hypertension;   Vascular Diseases;   Cardiovascular Diseases
Interventions:   Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
Sponsor:   Medtronic Vascular
Recruiting

Comparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT

Condition:   Coronary Stenosis
Intervention:   Diagnostic Test: OCT, FFR, CTA and FFRCT
Sponsor:   University Hospital Inselspital, Berne
Recruiting

Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction (BASILICA) Prospective Investigation

Condition:   Aortic Valve Failure
Intervention:   Device: ASHI_INTECC Astato XS 20 0.014 guidewire
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Not yet recruiting

STAT-STatin and Aspirin in Trauma

Conditions:   Wounds and Injuries;   Venous Thromboembolism
Interventions:   Drug: Aspirin and Rosuvastatin;   Drug: Placebo (for Aspirin and Rosuvastatin)
Sponsor:   Denver Health and Hospital Authority
Recruiting

Oral Factor XIa Inhibitor for the Prevention of New Ischemic Stroke in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)

Conditions:   Acute Ischemic Stroke;   Transient Ischemic Attack (TIA)
Interventions:   Drug: BMS-986177;   Other: BMS-986177 Placebo;   Drug: Clopidogrel;   Drug: Aspirin
Sponsors:   Bristol-Myers Squibb;   Janssen, LP
Recruiting

Epidural Anesthesia Within an Enhanced Recovery Pathway in Reducing Pain in Patients Undergoing Gynecologic Surgery

Conditions:   Intraoperative Complication;   Malignant Female Reproductive System Neoplasm;   Pain
Interventions:   Drug: Epidural analgesia;   Other: Intraoperative Complication Management and Prevention;   Procedure: Pain Therapy
Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI)
Recruiting

This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding

Condition:   Atrial Fibrillation
Intervention:   Drug: Idarucizumab
Sponsor:   Boehringer Ingelheim
Recruiting

Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications

Conditions:   Cardiovascular Diseases;   Adherence, Medication;   Medication Adherence;   Diabetes Mellitus;   Hypertension;   Hyperlipidemias;   Coronary Artery Disease;   Atrial Fibrillation
Intervention:   Behavioral: Nudge
Sponsors:   University of Colorado, Denver;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting

Conscious Sedation vs General Anesthesia in TAVR Patients

Condition:   Aortic Stenosis
Interventions:   Procedure: General Anesthesia;   Procedure: Conscious Sedation
Sponsor:   Montefiore Medical Center
Withdrawn

Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

Condition:   Hereditary Angioedema (HAE)
Intervention:  
Sponsor:   Shire
Recruiting

Ultrasound Study of the Diaphragm Evolution Under ECMO

Conditions:   Cardiogenic Shock;   Weaning Failure
Intervention:  
Sponsor:   Association Pro-arte
Completed

Analysis of Endotoxin Activity in Patients With ECMO

Conditions:   Cardiovascular Shock;   Respiratory Failure
Intervention:   Device: Extra-corporeal membrane oxygenation
Sponsor:   National Taiwan University Hospital
Not yet recruiting

Impact of Stress CT Myocardial Perfusion on Downstream Resources and Prognosis

Conditions:   Coronary Artery Disease;   Myocardial Ischemia
Interventions:   Diagnostic Test: Integration of CCTA with stress CTP when indicated;   Diagnostic Test: Standard of care approach
Sponsors:   Centro Cardiologico Monzino;   Medical University of South Carolina;   Semmelweis University Heart and Vascular Center;   Emory University;   UMC Utrecht;   Johns Hopkins University;   Policlinico Hospital
Not yet recruiting

Correlation of Genetic Polymorphisms and Clinical Parameters With the Complexity of Coronary Artery Disease

Conditions:   Coronary Artery Disease;   Cardiovascular Risk Factor;   Coronary Arteriosclerosis
Intervention:   Genetic: SNPs associated with CAD
Sponsors:   Aristotle University Of Thessaloniki;   LABNET IAE - Private Reference Diagnostic Laboratory
Active, not recruiting

Dialysis Training Therapy: The DiaTT Trial

Conditions:   Chronic Kidney Diseases;   Hemodialysis
Interventions:   Behavioral: Intradialytic exercise intervention;   Behavioral: Usual Care
Sponsors:   Prof. Dr. med. Martin Halle;   Technische Universität München;   University Hospital of Cologne;   KfH Kuratorium für Dialyse und Nierentransplantation;   Clinical Trials Unit Freiburg;   AOK PLUS;   BARMER;   Techniker Krankenkasse;   Federal Joint Committee, Germany
Recruiting

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

Condition:   Influenza A
Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
Sponsor:   Janssen Research & Development, LLC
Recruiting

Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics

Conditions:   Osteomyelitis;   Diabetes;   Amputation
Interventions:   Drug: Rifampin;   Drug: Riboflavin Placebo
Sponsor:   VA Office of Research and Development
Recruiting

Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy

Conditions:   Obstructive Sleep Apnea of Adult;   Preeclampsia;   Obstetrical Complications
Interventions:   Device: Continuous Positive Airway Pressure;   Other: Sleep Hygiene Control
Sponsors:   The George Washington University Biostatistics Center;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting

Forearm Blood Flow in Chronic Kidney Disease Subjects With Anemia (FBF-CKD)

Condition:   Anaemia
Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa (Aranesp);   Drug: Acetylcholine;   Drug: Sodium nitroprusside;   Drug: L-N-monomethyl arginine citrate (L-NMMA)
Sponsor:   GlaxoSmithKline
Recruiting

Hips Screws or (Total) Hip Replacement for Undisplaced Femoral Neck Fractures in Elderly Patients (HipSTHeR)

Conditions:   Femoral Neck Fractures;   Undisplaced Fracture
Interventions:   Device: Arthroplasty;   Device: Internal Fixation
Sponsors:   Uppsala University;   The Swedish Research Council
Not yet recruiting

Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery

Conditions:   Coronary Artery Bypass Graft Surgery;   Atherosclerosis;   Vein Occlusion
Interventions:   Drug: Evolocumab;   Other: Placebo
Sponsors:   St. Michael's Hospital, Toronto;   Applied Health Research Centre
Recruiting

Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation

Conditions:   Drug-Eluting Stents;   Percutaneous Coronary Intervention
Interventions:   Drug: 3 months DAPT;   Drug: 12 months DAPT
Sponsor:   Shanghai MicroPort Medical (Group) Co., Ltd.
Recruiting

OCT vs IVUS vs QCA to Guide Stent Implantation in the Treatment of Moderate-to-severe Calcified Lesion in Coronary Artery

Conditions:   Optical Coherence Tomography;   Intravascular Ultrasound;   Angiography
Interventions:   Device: OCT guidance;   Device: IVUS guidance;   Device: QCA
Sponsor:   Shanghai MicroPort Medical (Group) Co., Ltd.
Not yet recruiting

Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation

Condition:   Foramen Ovale, Patent
Interventions:   Drug: Aspirin;   Device: Cardiovascular Implantable Device (CIED);   Device: Gore Cardioform Septal Occluder
Sponsor:   Mayo Clinic
Not yet recruiting

EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Evolocumab 140 mg/mL;   Drug: Placebo
Sponsors:   University Hospital Inselspital, Berne;   Amgen;   University of Bern
Active, not recruiting

AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)

Condition:   Post-Operative Atrial Fibrillation
Interventions:   Device: AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems;   Drug: Anticoagulation Therapy
Sponsor:   AtriCure, Inc.
Completed

HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

Condition:   Kidney Cancer
Intervention:   Biological: cell infusion
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Loyola University Medical Center (LUMC)
Recruiting

Post-Embolic Rhythm Detection With Implantable Versus External Monitoring

Conditions:   Stroke;   Atrial Fibrillation;   Arrhythmias, Cardiac
Interventions:   Device: Medtronic Reveal LINQ;   Device: Sorin Spiderflash-t
Sponsors:   University of Alberta;   University of Calgary;   Alberta Innovates Health Solutions;   Medtronic
Active, not recruiting

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances

Conditions:   Immunosuppression;   Leukemia
Intervention:   Device: SOLEX 300i Stem Cell Selection
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed